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Clinical Research Article
Background:	Shivering	is	a	 frequent	event	during	spinal	anesthesia	and	meperidine	is	a	well-known	effective	
drug	for	prevention	and	treatment	of	shivering.	Nefopam	is	a	non-opiate	analgesic	and	also	known	to	have	an	
anti-shivering	effect.	We	compared	nefopam	with	meperidine	for	efficacy	of	prevention	of	shivering	during	spinal	
anesthesia.	
Methods:	Sixty	 five	patients,	American	Society	of	Anesthesiologists	physical	status	I	or	 II,	aged	20-65	years,	
scheduled	for	elective	orthopedic	surgery	under	spinal	anesthesia	were	investigated.	Patients	were	randomly	divided	
into	two	groups,	meperidine	(Group	M,	n	=	33)	and	nefopam	(Group	N,	n	=	32)	groups.	Group	M	and	N	received	
meperidine	0.4	mg/kg	or	nefopam	0.15	mg/kg,	respectively,	 in	100	ml	of	isotonic	saline	intravenously.	All	drugs	
were	infused	for	15	minutes	by	a	blinded	investigator	before	spinal	anesthesia.	Blood	pressures,	heart	rates,	body	
temperatures	and	side	effects	were	checked	before	and	at	15,	30,	and	60	minutes	after	spinal	anesthesia.	
Results:	The	incidences	and	scores	of	shivering	were	similar	between	the	two	groups.	The	mean	arterial	pressures	
in	Group	N	were	maintained	higher	than	in	Group	M	at	15,	30,	and	60	minutes	after	spinal	anesthesia.	The	injection	
pain	was	checked	in	Group	N	only	and	its	incidence	was	15.6%.
Conclusions:	We	conclude	that	nefopam	can	be	a	good	substitute	for	meperidine	for	prevention	of	shivering	during	
spinal	anesthesia	with	more	stable	hemodynamics,	if	injection	pain	is	effectively	controlled.	(Korean	J	Anesthesiol	
2013;	64:	229-233)
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Introduction
Shivering	associated	with	spinal	anesthesia	is	a	frequent	
event,	and	the	reported	median	incidence	of	shivering	related	
to	neuraxial	anesthesia	is	up	to	55%	[1].	The	mechanism	of	
shivering	 in	patients	undergoing	spinal	anesthesia	 is	not	
clear,	but	hypothermia	due	to	redistribution	of	heat	caused	by	
vasodilation	below	the	level	of	a	neuraxial	block	is	suggested.	
Spinal	anesthesia	also	impairs	the	thermoregulation	system	by	
inhibiting	vasoconstriction.	
Shivering	increases	oxygen	consumption,	metabolic	rate,	
lactic	acidosis,	carbon	dioxide	production,	plasma	catecho-
lamines,	and	cardiac	output.	Shivering	movement	may	interfere	
with	monitoring	of	hemodynamics	as	well	as	increasing	patient	
discomfort	and	distress.	Therefore,	 it	 is	very	 important	 to	
prevent	shivering	during	spinal	anesthesia.	
Many	pharmacological	trials	for	prevention	or	treatment	
of	shivering	during	spinal	anesthesia	have	been	tried	by	using	
drugs	like	fentanyl,	meperidine,	clonidine,	and	tramadol,	etc	
[1].	The	studies	using	fentanyl	were	via	epidural	or	intrathecal	
injection	and	there	is	no	study	for	intravenous	injection	[1-4].	
Ketamine	can	also	decrease	shivering	during	spinal	anesthesia,	
but	 its	property	of	stimulating	sympathetic	nervous	system	
induces	increasing	blood	pressure,	heart	rate,	secretion,	and	
hallucination.	These	make	the	restrictive	use	of	ketamine	[1,5,6].	
When	clonidine	was	 injected	 intravenously,	shivering	was	
effectively	treated,	but	hypotension	and	bradycardia	occurred	
[7-9].	There	are	many	studies	for	meperidine	via	intravenous,	
intrathecal,	and	epidural	administrations	[1,10,11].	Meperidine	
was	very	effective	for	prevention	and	treatment	of	shivering	
after	general	and	neuraxial	anesthesia,	but	hypotension	and	
drowsiness	occurred	frequently	as	the	side	effects.	
Nefopam	is	a	non-opiate,	non-sedative	analgesic	and	also	
known	as	effective	 for	 treatment	of	shivering	after	general	
anesthesia	[1,12].	It	does	not	induce	respiratory	depression	and	
drowsiness.	If	nefopam	is	effective	for	prevention	of	shivering	
during	spinal	anesthesia	without	side	effects,	it	may	be	a	better	
substitute	for	meperidine.	Therefore,	we	compared	nefopam	with	
meperidine	for	preventive	effects	for	shivering,	hemodynamics,	
and	side	effects	during	spinal	anesthesia.
Materials and Methods
This	study	was	a	prospective,	double	blind,	randomized,	
controlled	study.	After	the	approval	of	the	institute’s	ethics	
committee	and	obtaining	written	informed	consents,	65	patients	
of	American	Society	of	Anesthesiologists	physical	status	I	or	II,	
aged	20-65	years,	undergoing	spinal	anesthesia	for	elective	
orthopedic	surgery	were	investigated.	Patients	with	uncontrolled	
hypertension,	diabetes	mellitus,	hepatic	or	pulmonary	disease,	
and	fever	(temperature	>	38oC)	were	excluded.	The	surgical	
procedures	included	arthroscopic	surgery	of	knee	or	ankle,	
hallus	valgus	correction,	total	ankle	replacement,	open	tibia	
osteotomy,	hardware	removal	of	lower	extremities,	excision	of	
benign	mass,	and	tendon	repair.
Patients	were	randomly	divided	into	two	groups	to	receive	
meperidine	(Group	M)	or	nefopam	(Group	N).	Meperidine	0.4	
mg/kg	or	nefopam	0.15	mg/kg	was	prepared	and	each	drug	was	
mixed	into	100	ml	isotonic	saline.	In	order	to	facilitate	blinding,	
the	test	solution	was	prepared	by	an	anesthetic	nurse	who	was	
not	involved	in	the	present	study.	Neither	the	anesthesiologist	
nor	the	patient	was	aware	of	 the	kind	of	a	drug.	The	study	
drugs	were	infused	intravenously	to	the	patients	for	15	minutes	
just	before	spinal	anesthesia.	The	ambient	temperatures	of	
the	operating	rooms	were	maintained	at	22oC	and	no	active	
warming	for	patients	was	used.	
All	patients	received	5	ml/kg	of	lactated	Ringer’s	solution	
before	spinal	anesthesia	without	any	premedication.	Spinal	
anesthesia	was	performed	with	a	25-G	Quincke	spinal	needle	
between	the	L3-4	interspinal	space	in	the	lateral	decubitus	
position	and	11-13	mg	of	0.5%	hyperbaric	bupivacaine	was	
injected	intrathecally.	Bupivacaine	doses,	sensory	block	levels,	
and	durations	of	 surgery	were	checked,	and	mean	blood	
pressures,	heart	rates,	and	tympanic	membrane	temperatures	
were	measured	before	(baseline)	and	at	15,	30,	and	60	min	after	
spinal	anesthesia.	Sensory	block	levels	were	tested	by	using	
alcohol	swabs	every	5	minutes	after	intrathecal	injection	to	find	
maximal	heights	of	sensory	block.	Also,	sedation	scores	and	
shivering	scores	were	checked	till	60	min	after	spinal	anesthesia.	
Sedation	score	was	graded	using	the	Ramsay	sedation	scale,	
and	shivering	score	was	graded	as;	0	=	no	shivering,	1	=	slightly	
shivering,	2	=	muscle	shivering,	and	3	=	severe	muscle	shivering.	
Side	effects,	 such	as	hypotension,	nausea	and	vomiting,	
pruritus,	respiratory	depression	(SpO2	<	95),	and	injection	
pain	were	recorded.	Hypotension	was	defined	as	a	decrease	in	
mean	blood	pressure	of	more	than	20%	from	the	baseline	or	
below	60	mmHg,	and	checked	and	treated	with	ephedrine	4	mg	
repeatedly	if	occurred.	
All	statistical	analysis	was	performed	with	PASWⓇ	statistics	
(version	18	SPSS,	Chicago,	IL,	USA).	Demographic	data,	bupi-
vacaine	doses,	durations	of	surgery,	sensory	block	 levels,	
mean	arterial	pressures,	heart	rates,	and	tympanic	membrane	
temperatures	between	the	groups	were	compared	using	the	
Student’s	t-test.	The	incidences	of	side	effects	and	scores	of	
shivering	and	sedation	scales	were	analyzed	with	the	chi-square	
test	and	Fisher’s	exact	test.	Correlation	among	variables	was	
analyzed	with	Pearson’s	correlation	coefficient.	P	value	of	<0.05	
was	considered	as	statistically	significant.
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Results
There	was	no	difference	between	the	groups	with	respect	
to	demographic	data,	patients’	characteristics	related	to	spinal	
anesthesia,	bupivacaine	doses,	durations	of	surgery	and	sensory	
block	levels	(Table	1).	
The	mean	arterial	pressures	in	Group	N	were	maintained	
higher	than	in	Group	M	at	15,	30,	and	60	minutes	after	spinal	
anesthesia	(P	=	0.001,	0.014,	and	0.026	at	15,	30,	and	60	minutes,	
respectively,	after	spinal	anesthesia,	Fig.	1).	The	mean	arterial	
pressures	and	heart	rates	 in	Group	M	were	 lower	than	the	
baseline	values	of	each	parameter	at	15,	30,	and	60	minutes	after	
spinal	anesthesia	(P	=	0.001,	0.002,	and	0.010	for	mean	arterial	Table 1. Demographic Data and Patients’ Characteristics Related to 
Spinal Anesthesia
Group M
(n = 33)
Group N
(n = 32)
Age (yr)
Gender (M/F)
Weight (kg)
Height (cm)
ASA (I/II)
Bupivacaine dose (mg)
Duration of surgery (min)
Sensory block level
40.5 ± 15.9
15/18
66.2 ± 12.9
165.8 ± 9.0
28/5
11.3 ± 1.2
72.0 ± 46.8
T6 (T1-L1)
39.5 ± 17.2
18/14
70.2 ± 14.5
167.0 ± 9.8
25/7
11.3 ± 1.3
82.6 ± 50.8
T4 (T1-T11)
Values are mean ± SD. Sensory block level was expressed as median 
value. Group M: meperidine group, Group N: nafopam group. ASA: 
American Society of Anesthesiologists physical status.
Table 2. Incidences of Side Effects
Group M
(n = 33)
Group N
(n = 32)
Shivering score (n, 0/1/2/3)
Nausea (n)
Respiratory depression (n)
Sedation score (n, 2/3/4)
Pruritus (n)
Injection pain (n)
30/2/1/0
7/33 (21.2%)
0/33 (0.0%)
30/2/1
1/33 (3.0%)
0 (0%)
32/0/0/0
1/32 (3.1%)
0/32 (0.0%)
26/6/0
0/32 (0.0%)
 5 (15.6%)*
Values are number of patients (%). Group M: meperidine group, 
Group N: nefopam group. *P < 0.05, compared to Group M.
Fig. 1. Change of hemodynamics and body temperature. (A) mean 
arterial pressure, (B) heart rate, and (C) tympanic membrane tem pe-
rature. Group M: meperidine group, Group N: nafopam group. *P < 0.05, 
compared to Group M at the same times. †P < 0.05, compared to the 
baseline value of the same group.
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pressures,	and	P	=	0.031,	0.003,	and	0.007	for	heart	rates,	at	15,	30,	
and	60	minutes,	respectively,	after	spinal	anesthesia,	Fig.	1).	The	
tympanic	membrane	temperatures	were	not	different	between	
the	groups	except	at	60	minutes	after	spinal	anesthesia	(Fig.	1).	
There	was	no	hypotension	or	vomiting	in	both	groups.	The	
sedation	scores,	shivering	scores,	and	the	incidences	of	nausea,	
respiratory	depression	and	pruritus	were	not	different	between	
the	groups	(Table	2).	Although	not	statistically	significant,	
the	incidence	of	nausea	in	Group	M	was	much	higher	than	in	
Group	N	(7/33	vs.	1/32,	P	=	0.054)	and	it	was	not	correlated	with	
sensory	block	levels	(P	=	0.778).	Injection	pain	was	observed	in	
Group	N	only	and	its	incidence	was	15.6%	(P	=	0.024,	Table	2).
Discussion
Nefopam	is	a	non-opioid,	non-steroidal	centrally-acting	
analgesic.	Its	chemical	class	is	benzoxazocine	which	is	struc-
tually	related	to	diphenhydramine	(an	antihistamine	drug)	
and	orphenadrine	(an	antimuscarinic	drug).	It	is	used	mainly	in	
European	countries	for	the	relief	of	moderate	to	severe	pain	as	an	
alternative	to	opioid	analgesics.	Its	mechanism	underlying	the	
pharmacological	actions	is	not	clear,	but	it	is	suggested	that	the	
inhibition	of	synaptosomal	uptake	of	serotonin,	norepinephrine	
and	dopamine	is	related	to	its	analgesic	properties	[13-17].	
Nefopam	also	directly	interacts	with	α2-adrenoceptors	[14]	and	
is	a	noncompetitive	NMDA	receptor	antagonist	[18].	Nefopam	
has	an	additional	action	of	the	prevention	of	shivering	and	it	is	
related	to	inhibition	of	monoamine	and	NMDA	receptors.	
Because	nefopam	does	not	produce	respiratory	depression,	
sedation	and	hypotension,	it	was	usually	studied	for	analgesics	
in	critically	ill	patients	[19]	or	for	prevention	of	postoperative	
shivering	due	to	hypothermia	[20-22].	Bilotta	et	al.	[12]	first	
reported	that	nefopam	was	superior	to	tramadol	for	prevention	
of	shivering	during	neuraxial	anesthesia.	Our	study	is	also	the	
first	in	comparing	nefopam	with	meperidine	for	prevention	
of	 shivering	during	 spinal	 anesthesia.	 In	our	 study,	 the	
prophylactic	administration	of	nefopam	reduced	the	incidences	
and	scores	of	shivering	during	spinal	anesthesia	similar	to	
meperidine.	
In	the	study	of	Bilotta	et	al.	 [12],	there	was	no	difference	
between	nefopam	and	tramadol	in	hemodynamics.	However,	
in	our	study,	nefopam	maintained	blood	pressure	higher	
compared	with	meperidine.	While	most	thermoregulatory	drugs	
including	meperidine	reduce	both	the	thresholds	of	shivering	
and	vasoconstriction,	Alfonsi	et	al.	[23]	reported	that	nefopam	
significantly	reduced	only	the	shivering	threshold.	These	are	
clinically	important	because	thermoregulatory	vasodilation	can	
induce	reduction	of	nearly	20	mmHg	in	mean	arterial	pressure.	
Maintaining	higher	blood	pressure	may	be	due	to	the	property	
of	nefopam	sparing	vasoconstriction	threshold.
Another	advantage	of	nefopam	is	that	nefopam	does	not	
induce	respiratory	depression.	In	this	study,	there	was	no	case	
of	respiratory	depression	in	the	nefopam	group	same	as	in	the	
meperidine	group.	It	means	that	nefopam	can	be	used	safely	
for	prevention	of	shivering	during	spinal	anesthesia	in	critically	
ill	patients	with	hemodynamic	instability	because	the	risks	of	
repiratory	depression	together	with	sedation	and	hypotension	
can	be	excluded	or	minimized.	Especially,	it	is	expected	that	
nefopam	can	reduce	severe	postoperative	morbidities	such	
as	myocardial	infarction	by	preventing	the	increase	of	oxygen	
consumption	due	to	shivering.	
Common	side	effects	of	nefopam	are	sweating,	nausea,	
tachycardia	and	pain	at	injection,	etc	[20,24,25].	However,	in	
our	study,	 there	was	no	sweating	or	 tachycardia.	Although	
the	incidence	of	nausea	was	not	different	between	the	two	
groups	statistically,	nausea	was	more	frequently	observed	in	
the	meperidine	group	than	in	the	nefopam	group	and	it	was	
not	correlated	with	the	sensory	block	levels.	Pain	at	injection	
was	observed	in	the	nefopam	group	only	and	it	is	considered	
to	be	related	to	 the	rapid	 infusion	of	nefopam.	It	 resolved	
spontaneously	within	30	minutes	 in	all	cases	and	this	may	
suggest	that	the	injection	pain	is	associated	with	rapid	increases	
in	cerebral	concentration	of	nefopam	[20].	
The	limitations	of	this	study	are	three.	First,	we	used	the	
duration	of	15	minutes	for	infusion	of	meperidine	or	nefopam.	
The	usual	recommendation	for	intravenous	administration	of	
nefopam	is	slow	infusion	over	15	minutes	or	more.	Moreover,	
the	dilution	of	the	nefopam	with	100	ml	of	isotononic	saline	
was	 thought	 to	be	sufficient	 to	prevent	 the	 injection	pain	
by	tight	control	of	slow	infusion.	However,	in	our	study,	five	
patients	complained	of	pain	at	injection	of	nefopam	on	their	
limbs	with	IV	access.	Thus,	it	is	thought	that	the	injection	pain	
can	be	prevented	or	reduced	by	slower	infusion	of	nefopam.	
Second,	the	overall	sensory	block	levels	in	the	two	groups	were	
high.	It	may	produce	an	unexpected	bias	in	the	incidences	of	
side	effects.	Third,	the	study	duration	for	each	subject	was	short	
as	60	minutes.	Actually,	we	focused	on	the	effect	of	nefopam	
to	prevent	shivering	by	spinal	anesthesia	itself	because	the	
kinds	and	duration	of	surgery	may	affect	the	core	temperature	
by	cooling	the	body.	So,	we	chose	the	study	duration	of	60	
minutes.	However,	it	is	thought	that	the	incidence	and	degree	of	
shivering	during	the	intraoperative	and	postoperative	period	is	
also	meaningful	because	the	presence	or	absence	of	shivering	is	
more	important	for	a	patient.
In	summary,	nefopam	demonstrated	a	preventive	effect	
for	shivering	during	spinal	anesthesia	similar	as	meperidine.	
However,	nefopam	has	significant	injection	pain,	presumed	
to	be	due	to	rapid	infusion.	If	we	can	determine	the	infusion	
rate	of	nefopam	which	will	not	induce	injection	pain,	it	will	be	
more	helpful	and	comfortable	to	conscious	patients	requiring	
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the	prevention	or	treatment	of	shivering.	Therefore,	 further	
investigations	to	reduce	or	prevent	injection	pain	of	nefopam	
are	needed.	Nefopam	maintained	mean	arterial	pressures	more	
stable	than	meperidine.	It	implies	that	nefopam	can	be	a	good	
substitute	for	meperidine	for	prevention	of	shivering	during	
spinal	anesthesia	 in	hemodynamically	unstable	patients,	 if	
injection	pain	is	effectively	controlled.
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